Status:
COMPLETED
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Lead Sponsor:
AbbVie
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult particip...
Eligibility Criteria
Inclusion
- Newly-diagnosed AML and eligible to receive venetoclax as per local label.
- Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.
Exclusion
- \- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Key Trial Info
Start Date :
December 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 24 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05215639
Start Date
December 27 2021
End Date
November 24 2025
Last Update
December 10 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Klagenfurt am Wörthersee /ID# 247304
Klagenfurt, Carinthia, Austria, 9020
2
Universitaetsklinikum St. Poelten /ID# 247283
Sankt Pölten, Lower Austria, Austria, 3100
3
Krankenhaus der Barmherzigen Brueder Graz /ID# 254121
Graz, Styria, Austria, 8020
4
Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 254174
Leoben, Styria, Austria, 8700